Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer

ABSTRACT: IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer

PROVIDER: PRJNA622728 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11470727_1.fastq.gz	Fastqsanger.gz
	SRR11470727_2.fastq.gz	Fastqsanger.gz
	SRR11470728_1.fastq.gz	Fastqsanger.gz
	SRR11470728_2.fastq.gz	Fastqsanger.gz
	SRR11470729_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 60

Similar Datasets

IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer

Project description:We identified IGF2BP1 as a marker of the C5 molecular subtype of high-grade ovarian carcinoma (HG-SOC). IGF2BP1 promotes SRC activity and ERK2 expression enhancing the tolerance towards SRC- and MEK-directed inhibitors saracatinib and selumetib. Combination treatment overcomes IGF2BP1-promoted resistance.

2020-08-24 | GSE147980 | GEO

IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer.

Project description:Epithelial-to-mesenchymal transition (EMT) is a hallmark of aggressive, mesenchymal-like high-grade serous ovarian carcinoma (HGSOC). The SRC kinase is a key driver of cancer-associated EMT promoting adherens junction (AJ) disassembly by phosphorylation-driven internalization and degradation of AJ proteins. Here, we show that the IGF2 mRNA-binding protein 1 (IGF2BP1) is up-regulated in mesenchymal-like HGSOC and promotes SRC activation by a previously unknown protein-ligand-induced, but RNA-independent mechanism. IGF2BP1-driven invasive growth of ovarian cancer cells essentially relies on the SRC-dependent disassembly of AJs. Concomitantly, IGF2BP1 enhances ERK2 expression in an RNA-binding dependent manner. Together this reveals a post-transcriptional mechanism of interconnected stimulation of SRC/ERK signalling in ovarian cancer cells. The IGF2BP1-SRC/ERK2 axis is targetable by the SRC-inhibitor saracatinib and MEK-inhibitor selumetinib. However, due to IGF2BP1-directed stimulation, only combinatorial treatment effectively overcomes the IGF2BP1-promoted invasive growth in 3D culture conditions as well as intraperitoneal mouse models. In conclusion, we reveal an unexpected role of IGF2BP1 in enhancing SRC/MAPK-driven invasive growth of ovarian cancer cells. This provides a rationale for the therapeutic benefit of combinatorial SRC/MEK inhibition in mesenchymal-like HGSOC.

| S-EPMC7951963 | biostudies-literature

Detection of IGF2BP1 phosphorylation in vitro and in vivo via Pro-Alanase treatment

Project description:In this project we aim to identify phosphorylation sites of IGF2BP1 that have not been discovered yet in mass spec experiments due to insufficient coverage. To this end we used Pro-Alanase treatment that produced detectable peptides in regions that are not covered by commonly used approaches. IGF2BP1 phosphorylation was investigated in vitro by treating purified IGF2BP1 with Src and in vivo by comparing immunoprecipitated IGF2BP1 from unstressed and stressed (1.5 h thapsigargin or 2 h or arsenite) HEK293T cells expressing GFP-labeled IGF2BP1.

2024-11-13 | PXD056497 | Pride

The IGF2BP1 oncogene is a druggable m6A-dependent enhancer of YAP1-driven gene expression in tumor growth

Project description:The Hippo/YAP1 signaling pathway regulates normal development by controlling contact inhibition of growth. In cancer, YAP1 activation is often dysregulated, leading to excessive tumor growth and metastasis. We demonstrate that the RNA-binding protein IGF2BP1 impedes the repression of YAP1 by Hippo signaling in carcinomas. IGF2BP1 stabilizes YAP1 mRNA and enhances YAP1 protein synthesis through an m6A-dependent interaction with the 3’UTR of the YAP1 mRNA. This results in increased nuclear YAP1 accumulation in IGF2BP1-expressing ovarian cancer, boosting transcriptional activity and bypassing contact inhibition. Inhibiting IGF2BP1-mRNA binding using the small molecule BTYNB reduces YAP1 levels and transcriptional activity, leading to significant growth inhibition in carcinoma cells and ovarian cancer organoids. Conversely, SRC inhibition via Saracatinib only impacts epithelial-like tumor cells, suggesting that the impact of SRC is limited by the stalling of YAP1 at adherens junction. This is particularly significant in de-differentiated, rather mesenchymal carcinoma-derived cells, which exhibit high IGF2BP1 and YAP1 expression, rendering them less reliant on SRC -directed growth stimulation. In such invasive carcinoma models, the combined inhibition of SRC and IGF2BP1 or YAP1/TAZ by Verteporfin proved superior over monotherapies. These findings highlight the therapeutic potential of targeting IGF2BP1, a key regulator of oncogenic transcription networks.

2024-12-09 | GSE283587 | GEO

m6A modification profile in primary microglia with/without Igf2bp1 knockdown

Project description:Our study demonstrated that the expression of Igf2bp1 in activated microglia was significantly up-regulated, implying a role of Igf2bp1 in LPS-induced m6A modifications in microglia. To understand the roles of Igf2bp1 on LPS-induced m6A modification in microglia, we performed Igf2bp1 loss-of-function (LOF) approach. Microglia stimulated by LPS were transfected with either scrambled siRNA control or Igf2bp1 siRNA for 48 hours. To m6A modification profiles in control and Igf2bp1 LOF microglia were determined by MeRIP-seq analysis.

2022-12-31 | E-MTAB-11411 | biostudies-arrayexpress

IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner [IGF2BP1 and SRF KD in ES-2 (total RNA)]

Project description:The oncofetal mRNA-binding protein IGF2BP1 and the transcriptional regulator SRF modulate gene expression in cancer. In cancer cells, we demonstrate that IGF2BP1 promotes the expression of SRF in a conserved and N6-methyladenosine (m6A) dependent manner by impairing the miRNA-directed decay of the SRF mRNA. This results in enhanced SRF-dependent transcriptional activity and promotes tumor cell growth and invasion. At the post-transcriptional level, IGF2BP1 sustains the expression of various SRF-target genes. The majority of these SRF/IGF2BP1-enhanced genes, including PDLIM7 and FOXK1, shows conserved upregulation with SRF and IGF2BP1 synthesis in cancer. PDLIM7 and FOXK1 promote tumor cell growth and were reported to enhance cell invasion. Consistently, 35 SRF/IGF2BP1-dependent genes showing conserved association with SRF and IGF2BP1 expression indicate a poor overall survival probability in ovarian, liver and lung cancer. In conclusion, these findings identify the SRF/IGF2BP1-, miRNome- and m6A-dependent control of gene expression as a conserved oncogenic driver network in cancer.

2018-10-10 | GSE116059 | GEO

Stromal inflammation is a targetable driver of hematopoietic aging [Microarray analysis]

Project description:Stromal inflammation is a targetable driver of hematopoietic aging [Microarray analysis]

| PRJNA713346 | ENA

Stromal inflammation is a targetable driver of hematopoietic aging [droplet-based scRNAseq]

Project description:Stromal inflammation is a targetable driver of hematopoietic aging [droplet-based scRNAseq]

| PRJNA708338 | ENA

IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner [miRNA-seq]

2018-10-10 | GSE116179 | GEO

IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner [Huh-7]

2018-10-10 | GSE116133 | GEO